Content deleted Content added
Verified72 (talk | contribs) No edit summary |
Arthurfragoso (talk | contribs) + Legal status in Brazil: F2 (Prohibited psychotropics) |
||
(40 intermediate revisions by 27 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{Drugbox |
{{Drugbox |
||
| Watchedfields = changed |
|||
| verifiedrevid = |
| verifiedrevid = 446619973 |
||
| IUPAC_name |
| IUPAC_name = 4-Methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone |
||
| image |
| image = JWH-081.svg |
||
⚫ | |||
⚫ | |||
<!--Clinical data--> |
|||
⚫ | |||
| tradename = |
|||
⚫ | |||
| |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
||
⚫ | |||
⚫ | |||
⚫ | |||
| molecular_weight = 371.47 g/mol |
|||
⚫ | |||
⚫ | |||
| |
| legal_BR = F2 |
||
| legal_BR_comment = <ref>{{Cite web |author=Anvisa |author-link=Brazilian Health Regulatory Agency |date=2023-07-24 |title=RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial |trans-title=Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control|url=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-804-de-24-de-julho-de-2023-498447451 |url-status=live |archive-url=https://web.archive.org/web/20230827163149/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-804-de-24-de-julho-de-2023-498447451 |archive-date=2023-08-27 |access-date=2023-08-27 |publisher=[[Diário Oficial da União]] |language=pt-BR |publication-date=2023-07-25}}</ref> |
|||
⚫ | |||
| legal_CA = Schedule II |
|||
⚫ | |||
| legal_UK = Class B |
|||
⚫ | |||
| legal_US = Schedule I |
|||
⚫ | |||
| legal_DE = Anlage II |
|||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|||
⚫ | | legal_status = I-N (Poland)<ref>{{cite web | title = Ustawa z dnia 15 kwietnia 2011 r. o zmianie ustawy o przeciwdziałaniu narkomanii (Dz.U. 2011 nr 105 poz. 614) |url= http://isap.sejm.gov.pl/DetailsServlet?id=WDU20111050614 |publisher= Internetowy System Aktów Prawnych |access-date= 12 June 2011}}</ref> |
||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
<!--Pharmacokinetic data--> |
|||
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
|||
| bioavailability = |
|||
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|||
⚫ | |||
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
<!--Identifiers--> |
|||
| CAS_number_Ref = {{cascite|correct|??}} |
|||
⚫ | |||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = 77E58024IT |
|||
⚫ | |||
⚫ | |||
⚫ | |||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|||
| DrugBank = |
|||
| ChemSpiderID = 8722599 |
|||
<!--Chemical data--> |
|||
⚫ | |||
⚫ | |||
| StdInChI = 1S/C25H25NO2/c1-3-4-9-16-26-17-22(19-11-7-8-13-23(19)26)25(27)21-14-15-24(28-2)20-12-6-5-10-18(20)21/h5-8,10-15,17H,3-4,9,16H2,1-2H3 |
|||
| StdInChIKey = UBMPKJKGUQDHRM-UHFFFAOYSA-N |
|||
}} |
}} |
||
⚫ | '''JWH-081''' is an [[analgesic]] chemical from the [[naphthoylindole]] family, which acts as a [[cannabinoid]] agonist at both the CB<sub>1</sub> and CB<sub>2</sub> receptors.<ref name="pmid10940540">{{cite journal | vauthors = Aung MM, Griffin G, Huffman JW, Wu M, Keel C, Yang B, Showalter VM, Abood ME, Martin BR | display-authors = 6 | title = Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding | journal = Drug and Alcohol Dependence | volume = 60 | issue = 2 | pages = 133–40 | date = August 2000 | pmid = 10940540 | doi = 10.1016/s0376-8716(99)00152-0 }}</ref> With a [[dissociation constant|K<sub>i</sub>]] of 1.2nM it is fairly selective for the CB<sub>1</sub> subtype, its affinity at this subtype is measured at approximately 10x the affinity at CB<sub>2</sub>(12.4nM).<ref name="pmid15582455">{{cite journal | vauthors = Huffman JW, Zengin G, Wu MJ, Lu J, Hynd G, Bushell K, Thompson AL, Bushell S, Tartal C, Hurst DP, Reggio PH, Selley DE, Cassidy MP, Wiley JL, Martin BR | display-authors = 6 | title = Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists | journal = Bioorganic & Medicinal Chemistry | volume = 13 | issue = 1 | pages = 89–112 | date = January 2005 | pmid = 15582455 | doi = 10.1016/j.bmc.2004.09.050 }}</ref> It was discovered by and named after [[John W. Huffman]]. |
||
JWH-081 may be neurotoxic to animals when administered in high doses.<ref>{{cite journal | vauthors = Cha HJ, Seong YH, Song MJ, Jeong HS, Shin J, Yun J, Han K, Kim YH, Kang H, Kim HS | display-authors = 6 | title = Neurotoxicity of Synthetic Cannabinoids JWH-081 and JWH-210 | journal = Biomolecules & Therapeutics | volume = 23 | issue = 6 | pages = 597–603 | date = November 2015 | pmid = 26535086 | pmc = 4624077 | doi = 10.4062/biomolther.2015.057 }}</ref> |
|||
⚫ | '''JWH-081''' is an [[analgesic]] chemical from the [[naphthoylindole]] family, which acts as a [[cannabinoid]] agonist at both the CB<sub>1</sub> and CB<sub>2</sub> receptors.<ref>Aung MM, Griffin G, Huffman JW, Wu |
||
==Legal status== |
|||
www.titaniumwf.com JWH To buy JWH-250, MDPV, JWH-073, JWH-210, JWH-307, JWH-203, JWH-018, 4-FMC, JWH-011 AM-1220, AM-2201, AM-2233, URB-597, Methoextamine (MXE), 2c-i (Premium) laboratory in China. |
|||
www.titaniumwf.com sending of substances in any country. |
|||
In the United States, JWH-081 is a [[Schedule I Controlled Substance]].<ref>[https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf Controlled Substances listed by the DEA]</ref> |
|||
⚫ | |||
As of October 2015, JWH-081 is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinese | access-date=1 October 2015 | archive-date=1 October 2015 | archive-url=https://web.archive.org/web/20151001222554/http://www.sfda.gov.cn/WS01/CL0056/130753.html | url-status=dead }}</ref> |
|||
⚫ | |||
*[[JWH-018]] |
*[[JWH-018]] |
||
*[[JWH-098]] |
*[[JWH-098]] |
||
Line 39: | Line 64: | ||
*[[JWH-210]] |
*[[JWH-210]] |
||
==References== |
== References == |
||
{{reflist}} |
|||
<references/> |
|||
{{Cannabinoids}} |
{{Cannabinoids}} |
||
{{Hallucinogens}} |
|||
⚫ | |||
[[Category:Designer drugs]] |
|||
[[Category:JWH cannabinoids]] |
[[Category:JWH cannabinoids]] |
||
[[Category:Naphthoylindoles]] |
[[Category:Naphthoylindoles]] |
||
[[Category:Phenol ethers]] |
[[Category:Phenol ethers]] |
||
[[Category:CB1 receptor agonists]] |
|||
⚫ |
Latest revision as of 04:17, 28 August 2023
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.230.181 |
Chemical and physical data | |
Formula | C25H25NO2 |
Molar mass | 371.480 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
JWH-081 is an analgesic chemical from the naphthoylindole family, which acts as a cannabinoid agonist at both the CB1 and CB2 receptors.[3] With a Ki of 1.2nM it is fairly selective for the CB1 subtype, its affinity at this subtype is measured at approximately 10x the affinity at CB2(12.4nM).[4] It was discovered by and named after John W. Huffman.
JWH-081 may be neurotoxic to animals when administered in high doses.[5]
Legal status[edit]
In the United States, JWH-081 is a Schedule I Controlled Substance.[6]
As of October 2015, JWH-081 is a controlled substance in China.[7]
See also[edit]
References[edit]
- ^ Anvisa (2023-07-24). "RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-07-25). Archived from the original on 2023-08-27. Retrieved 2023-08-27.
- ^ "Ustawa z dnia 15 kwietnia 2011 r. o zmianie ustawy o przeciwdziałaniu narkomanii (Dz.U. 2011 nr 105 poz. 614)". Internetowy System Aktów Prawnych. Retrieved 12 June 2011.
- ^ Aung MM, Griffin G, Huffman JW, Wu M, Keel C, Yang B, et al. (August 2000). "Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding". Drug and Alcohol Dependence. 60 (2): 133–40. doi:10.1016/s0376-8716(99)00152-0. PMID 10940540.
- ^ Huffman JW, Zengin G, Wu MJ, Lu J, Hynd G, Bushell K, et al. (January 2005). "Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists". Bioorganic & Medicinal Chemistry. 13 (1): 89–112. doi:10.1016/j.bmc.2004.09.050. PMID 15582455.
- ^ Cha HJ, Seong YH, Song MJ, Jeong HS, Shin J, Yun J, et al. (November 2015). "Neurotoxicity of Synthetic Cannabinoids JWH-081 and JWH-210". Biomolecules & Therapeutics. 23 (6): 597–603. doi:10.4062/biomolther.2015.057. PMC 4624077. PMID 26535086.
- ^ Controlled Substances listed by the DEA
- ^ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 1 October 2015.